Evidence map›Paper›PMID 39972270›Full record

ArticleBMC cancer2025

Chunxiao Sui, Kun Chen, Enci Ding, Rui Tan, Yue Li, Jie Shen, Wengui Xu, Xiaofeng Li

Abstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chunxiao Sui *Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Kun Chen *Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Enci DingDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, 300192, China.
Rui TanDepartment of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
Yue LiDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, 300192, China.
Jie ShenDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, 300192, China. shenjie_vip@126.com.
Wengui XuDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. wenguixy@yeah.net.
Xiaofeng LiDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. xli03@tmu.edu.cn.

Funding

National Natural Science Foundation of China 82272074
6 · The paper itself

Abstract

backgroundRadiomic models combining intratumoral with peritumoral features are potentially beneficial to enhance the predictive performance. This study aimed to identify the optimal

methodsA total of 135 HCC patients from two institutions were retrospectively included. Four peritumoral regions were defined by dilating tumor region with thicknesses of 2 mm, 4 mm, 6 mm, and 8 mm, respectively. Based on segmentation of intratumoral, peritumoral and integrated volume of interest (VOI), corresponding radiomic features were extracted respectively. After feature selection, a total of 15 intratumoral radiomic models were constructed based on five ensemble learning algorithms and radiomic features from three image modalities. Then, the optimal combination of ensemble learning algorithms and image modality in the intratumoral models was selected to develop subsequent peritumoral radiomic models and integrated radiomic models. Finally, a nomogram was developed incorporating the optimal radiomic model with clinical independent predictors to achieve an intuitive representation of the prediction model.

resultsAmong the intratumoral radiomic models, the one which combined PET/CT-based radiomic features with SVM classifier outperformed other models. With the addition of peritumoral information, the integrated model based on an integration of intratumoral and 2 mm-peritumoral VOI, was finally approved as the optimal radiomic model with a mean AUC of 0.831 in the internal validation, and a highest AUC of 0.839 (95%CI:0.718-0.960) in the external test. Furthermore, a nomogram incorporating the optimal radiomic model with HBV infection and TNM status, was able to predict the prognosis for HCC with an AUC of 0.889 (95%CI: 0.799-0.979).

conclusionsThe integrated intratumoral and peritumoral radiomic model, especially for a 2 mm peritumoral region, was verified as the optimal radiomic model to predict the overall survival of HCC. Furthermore, combination of integrated radiomic model with significant clinical parameter contributed to further enhance the prediction efficacy.

trial registrationThis study was a retrospective study, so it was free from registration.

Indexed as

Carcinoma, HepatocellularFluorodeoxyglucose F18Liver NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedEnsemble LearningFemaleHumansMachine LearningMaleMiddle AgedNomogramsPrognosisRadiomicsRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTHCCPeritumoralPrognosisRadiomics

Identifiers

PMID39972270
PMCPMC11841186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.